Arvinas Inc (NASDAQ:ARVN) Director Briggs Morrison acquired 2,500 shares of Arvinas stock in a transaction dated Tuesday, March 24th. The shares were bought at an average cost of $40.82 per share, with a total value of $102,050.00. Following the completion of the purchase, the director now owns 29,520 shares in the company, valued at $1,205,006.40. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Shares of Arvinas stock traded up $3.18 during midday trading on Thursday, hitting $44.00. The company’s stock had a trading volume of 4,524 shares, compared to its average volume of 401,671. The firm has a market capitalization of $1.48 billion, a P/E ratio of -20.85 and a beta of 2.44. The stock has a 50-day simple moving average of $46.71 and a 200-day simple moving average of $36.47. The company has a quick ratio of 8.86, a current ratio of 8.86 and a debt-to-equity ratio of 0.02. Arvinas Inc has a 1-year low of $14.06 and a 1-year high of $54.95.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Monday, March 16th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.02). The business had revenue of $4.89 million during the quarter, compared to analyst estimates of $4.77 million. Arvinas had a negative return on equity of 30.16% and a negative net margin of 163.56%. As a group, sell-side analysts predict that Arvinas Inc will post -2.47 earnings per share for the current year.

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald raised their price objective on Arvinas from $42.00 to $75.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. Wedbush raised their price objective on Arvinas from $39.00 to $60.00 and gave the stock an “outperform” rating in a research note on Friday, January 24th. Piper Sandler reissued a “buy” rating and set a $58.00 price objective on shares of Arvinas in a research note on Monday, March 16th. Piper Jaffray Companies raised their price objective on Arvinas from $35.00 to $58.00 and gave the stock an “overweight” rating in a research note on Monday, January 6th. Finally, Zacks Investment Research raised Arvinas from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research report on Tuesday, March 17th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Arvinas presently has an average rating of “Buy” and an average target price of $49.55.

Several institutional investors have recently modified their holdings of the company. Bank of Montreal Can boosted its stake in shares of Arvinas by 66.3% during the 4th quarter. Bank of Montreal Can now owns 2,677 shares of the company’s stock worth $110,000 after buying an additional 1,067 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in Arvinas in the fourth quarter worth about $48,000. California State Teachers Retirement System raised its position in Arvinas by 5.6% in the third quarter. California State Teachers Retirement System now owns 28,596 shares of the company’s stock worth $616,000 after acquiring an additional 1,508 shares during the period. Quantbot Technologies LP bought a new stake in Arvinas in the fourth quarter worth about $68,000. Finally, American International Group Inc. raised its position in Arvinas by 14.6% in the fourth quarter. American International Group Inc. now owns 13,284 shares of the company’s stock worth $546,000 after acquiring an additional 1,696 shares during the period. 77.22% of the stock is owned by institutional investors and hedge funds.

Arvinas Company Profile

Arvinas, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer.

See Also: Dividend Aristocrat Index

Insider Buying and Selling by Quarter for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.